BD Marks 1,000th BD Rhapsody System, Driving Scientific Breakthroughs via Single-Cell Multiomics
Rhea-AI Summary
BD (NYSE: BDX) announced a significant milestone with the placement of its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital of the University of Cambridge. The BD Rhapsody™ System, launched in 2017, is a leading single-cell multiomics analysis platform that has been cited in over 700 peer-reviewed publications.
The system enables researchers to analyze multiomic data from hundreds of thousands of single cells simultaneously, offering DNA, RNA, and protein analysis capabilities. The latest version, released in 2023, features enhanced sample processing and cell capture technology. BD is expanding the platform's capabilities with new launches, including the BD OMICS-One™ WTA Next Assay for early-access customers and the upcoming BD® OMICS-Guard Cryo for sample preservation.
Positive
- System has achieved strong market adoption with 1,000 installations since 2017
- Platform has been cited in over 700 peer-reviewed publications, demonstrating scientific validity
- Company is expanding product capabilities with new assays and features
- System integrates with other BD instruments, creating a comprehensive workflow solution
Negative
- None.
News Market Reaction – BDX
On the day this news was published, BDX gained 0.73%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
"Our research focuses on understanding the signaling pathways of immune cells and their role in driving inflammation in patients in intensive care," said Dr. Andrew Conway Morris, associate professor of anesthesia, Addenbrooke's Hospital of the University of
Since the BD Rhapsody™ instrument was introduced in 2017, it has been cited in more than 700 publications in peer-reviewed journals. The latest version, which launched in 2023, allows flexible sample processing and cell capture using a gentle, robust microwell-based cartridge technology, and proprietary BD molecular indexing technology. The captured cellular information is used to generate various types of libraries for next-generation sequencing applications, accelerating time to insight. The BD Rhapsody™ System is uniquely positioned in the cell sorting and analysis workflow with flow cytometry instruments, including the BD FACSDiscover™ S8 Cell Sorter and A8 Cell Analyzer.
"This milestone is a reflection of the critical customer need for a single-cell platform that can offer the right balance of high-performing multiomic assays, without compromising data quality, at the most affordable cost per cell," said Ranga Partha, PhD, VP of global marketing and strategic growth areas, BD Biosciences. "The rapid adoption of the BD Rhapsody™ System is a testament to the fast-evolving scientific need for one complete end-to-end portfolio of single-cell multiomics instruments, reagents, assays, and bioinformatic tools that also work seamlessly alongside leading cell sorters and analyzers."
Innovation around the BD Rhapsody™ System and its workflows continues with upcoming launches:
- BD OMICS-One™ WTA Next Assay is now available for early-access customers, enabling researchers to unlock more genetic information from individual cells at a lower cost-per-cell basis
- BD® OMICS-Guard Cryo will be available this year, enabling researchers to preserve samples for extended periods of time, allowing for batching of analysis
- Robust automation is in development to further standardize and speed workflows
The research of Dr. Andrew Conway Morris is funded by the Medical Research Council, LifeArc, and Addenbrooke's Charitable Trust.
The BD Rhapsody™ System will be featured at the following: Booth 447 at the 2025 Annual Meeting of American Society of Human Genetics (October 14-18 in
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media: | Investors: |
Fallon McLoughlin | Adam Reiffe |
Director, Public Relations | VP, Investor Relations |
201.258.0361 | 201.847.6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-marks-1-000th-bd-rhapsody-system-driving-scientific-breakthroughs-via-single-cell-multiomics-302557914.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What milestone did BD (NYSE: BDX) achieve with its Rhapsody System in 2025?
How many publications have cited the BD Rhapsody System since its launch?
What new products is BD launching for the Rhapsody System?
What capabilities does the BD Rhapsody System offer researchers?
When was the latest version of the BD Rhapsody System released?
